Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more
Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more
Basel, 26 January 2018 Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event in a... Read more
Basel, 24 January 2018 Reminder: Invitation to Roche’s Full Year Results 2017 Presentation Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00 PM PST (evening before) Release will be e-mailed and... Read more
Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more
Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more
Basel, 10 January 2018 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. (NASDAQ: RXDX) at a price of... Read more
Basel, 10 January 2018 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. (NASDAQ: RXDX) at a price of... Read more
Basel, 08 January 2018 Invitation to Roche’s Full Year Results 2017 Presentation Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00 PM PST (evening before) Release will be e-mailed and posted... Read more
Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more